Hi @ChinaSyndrome,
.For highly sought-after projects the course of ownership is far from clear.
For example :
GGG may become a cash box with great interest in RE projects in the next few weeks.
They may be considering investments in Africa, greenfield and/or otherwise.
They might decide to become a significant PEK SH at a price well below that paid by other SH.
No FIRB problems.
Not saying they will act, but the references below show that RE projects scoped at 2020 prices
are now very undervalued. What more could a whale want ? Krill ?
.refs :
1) 26/11/2020 @RenewablesKid2 ( post 49150852 )
The PRE:LSE Chairman infers NdPr Oxide sold at USD80/kg would make their RE project "extremely successful/economic"
2) 10/2/2022 : NdPr Oxide selling at USD157/kg (13% VAT included/Delivery to factory)
SMM ( URL )
.
How PEK ownership evolves, we can only guess.
- Forums
- ASX - By Stock
- PEK
- News: PEK Shenghe Resources to buy 19.9% of Australia's Peak Rare Earths
News: PEK Shenghe Resources to buy 19.9% of Australia's Peak Rare Earths, page-225
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PEK (ASX) to my watchlist
(20min delay)
|
|||||
Last
18.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.28M |
Open | High | Low | Value | Volume |
18.5¢ | 19.0¢ | 18.0¢ | $28.86K | 157.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 19879 | 18.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.0¢ | 11895 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 19879 | 0.180 |
5 | 542624 | 0.175 |
5 | 833674 | 0.170 |
4 | 282886 | 0.165 |
5 | 268156 | 0.160 |
Price($) | Vol. | No. |
---|---|---|
0.190 | 11895 | 1 |
0.195 | 71880 | 2 |
0.200 | 5500 | 1 |
0.210 | 66000 | 2 |
0.215 | 10807 | 2 |
Last trade - 15.41pm 15/07/2024 (20 minute delay) ? |
Featured News
PEK (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online